 |
|
 |
|
ADHD is a common neurobiological disorder with multiple genetic and environmental origins. |
BioBehavioral Diagnostics Company (BioBDx) develops diagnostic systems that aid clinicians in the objective assessment of behavioral and neurobiological disorders. The company's lead product, the Quotient™ ADHD System1, is the first FDA cleared2 test that offers medical professionals an office-based capability to conduct rapid, precise and objective patient assessments to aid in the diagnosis of ADHD. Using the Quotient™ ADHD System, healthcare professionals are able to precisely measure the three core symptoms of
ADHD (inattention, hyperactivity and impulsivity).
1. The Quotient™ ADHD System was formerly known as the MMAT/ADHD™ System.
2. FDA clearance of this product does not in any way denote FDA approval of the device.
BioBDx Announces Availability of Quotient™ ADHD System
View Press Release
Larry Dubé, Medical Technology Industry Veteran, joins BioBehavioral Diagnostics as VP of Operations
View Press Release